EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare disease: drug trial aims to tame EGPA inflammation
Disease control OngoingThis study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels and organs. The goal is to see if the drug helps patients reach remission (no symptoms and low steroid use) after 24 weeks. The trial is already done enroll…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated May 17, 2026 09:04 UTC
-
Spit test could predict drug response in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks for proteins in blood, saliva, and sputum that can show organ damage and predict how well patients with EGPA (a rare inflammatory disease) or severe asthma respond to the drug mepolizumab. Researchers will analyze samples from 90 participants before and after sta…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC